GlassScriptPhysician profile
Neeraj Ramakrishnan
NPI 1366070534
$1,345.68
in general payments reported to CMS, 2019-2025
23 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $265 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.69 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $309.03 | 2025 | Erleada, Rybrevant, Balversa |
| E.R. Squibb & Sons, L.L.C. | $127.32 | 2024-2025 | Opdualag, Opdivo |
| Beone Medicines USA, INC. | $101.97 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $81.55 | 2024-2025 | Tecentriq, Polivy |
| Astrazeneca Pharmaceuticals LP | $78.14 | 2024-2025 | Lynparza, Tagrisso |
| Abbvie INC. | $74.20 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $60.48 | 2024-2025 | Pyrukynd |
| Incyte Corporation | $53.71 | 2025 | Jakafi, Monjuvi, Zynyz |
| Celgene Corporation | $50.63 | 2025 | Reblozyl |
| Jazz Pharmaceuticals INC. | $38.03 | 2024 | |
| Adc Therapeutics America, INC. | $32.98 | 2025 | |
| Lilly USA, LLC | $32.26 | 2025 | Jaypirca, Verzenio |
| Syndax Pharmaceuticals, INC. | $31.71 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.82 | 2025 | |
| Pharmaessentia USA Corporation | $30.76 | 2025 | Besremi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $30.75 | 2025 | Trodelvy |
| Deciphera Pharmaceuticals INC. | $29.45 | 2025 | Romvimza, Qinlock |
| Daiichi Sankyo INC. | $29.00 | 2025 | Datroway |
| Beigene USA, INC. | $28.72 | 2024 | Brukinsa |
| Array Biopharma INC | $27.69 | 2025 | Lorbrena |
| Springworks Therapeutics, INC. | $25.85 | 2025 | Ogsiveo |
| Kyowa Kirin, INC. | $20.52 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Ramakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.